Circulating tumor cells are significantly useful in determining the status of disease progression rate and projection of therapy needed for tumor eradication. Further development of various tumor markers that can be used along with companion diagnostics to diagnose or monitor various forms of cancer are expected to boost usage rates of CTC tests in the coming years.
Circulating tumor cell detection test possesses the ability to detect, quantify, and analyze tumor cells in the blood of cancer patients. It includes enrichment, detection and analysis of the detected circulating tumor cells. Circulating tumor cells tests are applicable in the characterization of tumor cells through biochemical marker analysis. CTC isolation, detection, and molecular characterization systems find investigational application in prostate, breast, colon, head, neck, skin, lung, and pancreatic cancer
Growing incidences oncology diseases and the introduction of novel biotechnological methods that enable the isolation and quantitation of circulating tumor cells. Furthermore, other factors like early disease diagnosis, cost savings on multiple treatments, drug safety, patient compliance, and optimization of therapies are attributive for rising demand for the preventive medicine, thus influencing the demand for CTC tests.
On course of the forecast period it is expected that over 150 companion diagnostic on-label combinations and a range of personalized therapeutic drugs under clinical trials and development pipelines based on companion diagnostics. The level of adoption of companion diagnostics is expected to significantly increase after these obtain complete FDA approval and are commercialized fully.
The global market for Circulating Tumor Cell Diagnostics was estimated to be worth US$ 4840.3 million in 2023 and is forecast to a readjusted size of US$ 9239.7 million by 2030 with a CAGR of 9.2% during the forecast period 2024-2030
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Circulating Tumor Cell Diagnostics, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Circulating Tumor Cell Diagnostics by region & country, by Type, and by Application.
The Circulating Tumor Cell Diagnostics market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Circulating Tumor Cell Diagnostics.
Market Segmentation
By Company
Janssen Diagnostics
Advanced Cell Diagnostics
Aviva Biosciences
Biocept Inc
Biofluidica Inc.
CellTraffix Inc.
Clearbridge BioMedics Pte Ltd
Epic Sciences Inc.
Fluxion Biosciences Inc.
ScreenCell
Silicon Biosystems
Sysmex Corporation
Greiner Bio-One GmbH
AdnaGen AG
Apocell Inc
Biocep Ltd
Canopus Bioscience Ltd
Creatv Microtech Inc
Ikonisys Inc
IV Diagnostics Inc
Miltenyi Biotech GmbH
Nanostring Technologies Inc
Rarecells Diagnostics.
Vitatex Inc
Segment by Type:
CTC Enrichment
CTC Detection
CTC Analysis
Segment by Application
Tumorigenesis research
EMT biomarkers development
Cancer stem cell research
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Circulating Tumor Cell Diagnostics manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Circulating Tumor Cell Diagnostics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Circulating Tumor Cell Diagnostics in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Market Overview
1.1 Circulating Tumor Cell Diagnostics Product Introduction
1.2 Global Circulating Tumor Cell Diagnostics Market Size Forecast
1.3 Circulating Tumor Cell Diagnostics Market Trends & Drivers
1.3.1 Circulating Tumor Cell Diagnostics Industry Trends
1.3.2 Circulating Tumor Cell Diagnostics Market Drivers & Opportunity
1.3.3 Circulating Tumor Cell Diagnostics Market Challenges
1.3.4 Circulating Tumor Cell Diagnostics Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Circulating Tumor Cell Diagnostics Players Revenue Ranking (2023)
2.2 Global Circulating Tumor Cell Diagnostics Revenue by Company (2019-2024)
2.3 Key Companies Circulating Tumor Cell Diagnostics Manufacturing Base Distribution and Headquarters
2.4 Key Companies Circulating Tumor Cell Diagnostics Product Offered
2.5 Key Companies Time to Begin Mass Production of Circulating Tumor Cell Diagnostics
2.6 Circulating Tumor Cell Diagnostics Market Competitive Analysis
2.6.1 Circulating Tumor Cell Diagnostics Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Circulating Tumor Cell Diagnostics Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Circulating Tumor Cell Diagnostics as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 CTC Enrichment
3.1.2 CTC Detection
3.1.3 CTC Analysis
3.2 Global Circulating Tumor Cell Diagnostics Sales Value by Type
3.2.1 Global Circulating Tumor Cell Diagnostics Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Circulating Tumor Cell Diagnostics Sales Value, by Type (2019-2030)
3.2.3 Global Circulating Tumor Cell Diagnostics Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Tumorigenesis research
4.1.2 EMT biomarkers development
4.1.3 Cancer stem cell research
4.1.4 Others
4.2 Global Circulating Tumor Cell Diagnostics Sales Value by Application
4.2.1 Global Circulating Tumor Cell Diagnostics Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Circulating Tumor Cell Diagnostics Sales Value, by Application (2019-2030)
4.2.3 Global Circulating Tumor Cell Diagnostics Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Circulating Tumor Cell Diagnostics Sales Value by Region
5.1.1 Global Circulating Tumor Cell Diagnostics Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Circulating Tumor Cell Diagnostics Sales Value by Region (2019-2024)
5.1.3 Global Circulating Tumor Cell Diagnostics Sales Value by Region (2025-2030)
5.1.4 Global Circulating Tumor Cell Diagnostics Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Circulating Tumor Cell Diagnostics Sales Value, 2019-2030
5.2.2 North America Circulating Tumor Cell Diagnostics Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Circulating Tumor Cell Diagnostics Sales Value, 2019-2030
5.3.2 Europe Circulating Tumor Cell Diagnostics Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Circulating Tumor Cell Diagnostics Sales Value, 2019-2030
5.4.2 Asia Pacific Circulating Tumor Cell Diagnostics Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Circulating Tumor Cell Diagnostics Sales Value, 2019-2030
5.5.2 South America Circulating Tumor Cell Diagnostics Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Circulating Tumor Cell Diagnostics Sales Value, 2019-2030
5.6.2 Middle East & Africa Circulating Tumor Cell Diagnostics Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Circulating Tumor Cell Diagnostics Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Circulating Tumor Cell Diagnostics Sales Value
6.3 United States
6.3.1 United States Circulating Tumor Cell Diagnostics Sales Value, 2019-2030
6.3.2 United States Circulating Tumor Cell Diagnostics Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Circulating Tumor Cell Diagnostics Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Circulating Tumor Cell Diagnostics Sales Value, 2019-2030
6.4.2 Europe Circulating Tumor Cell Diagnostics Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Circulating Tumor Cell Diagnostics Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Circulating Tumor Cell Diagnostics Sales Value, 2019-2030
6.5.2 China Circulating Tumor Cell Diagnostics Sales Value by Type (%), 2023 VS 2030
6.5.3 China Circulating Tumor Cell Diagnostics Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Circulating Tumor Cell Diagnostics Sales Value, 2019-2030
6.6.2 Japan Circulating Tumor Cell Diagnostics Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Circulating Tumor Cell Diagnostics Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Circulating Tumor Cell Diagnostics Sales Value, 2019-2030
6.7.2 South Korea Circulating Tumor Cell Diagnostics Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Circulating Tumor Cell Diagnostics Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Circulating Tumor Cell Diagnostics Sales Value, 2019-2030
6.8.2 Southeast Asia Circulating Tumor Cell Diagnostics Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Circulating Tumor Cell Diagnostics Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Circulating Tumor Cell Diagnostics Sales Value, 2019-2030
6.9.2 India Circulating Tumor Cell Diagnostics Sales Value by Type (%), 2023 VS 2030
6.9.3 India Circulating Tumor Cell Diagnostics Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Janssen Diagnostics
7.1.1 Janssen Diagnostics Profile
7.1.2 Janssen Diagnostics Main Business
7.1.3 Janssen Diagnostics Circulating Tumor Cell Diagnostics Products, Services and Solutions
7.1.4 Janssen Diagnostics Circulating Tumor Cell Diagnostics Revenue (US$ Million) & (2019-2024)
7.1.5 Janssen Diagnostics Recent Developments
7.2 Advanced Cell Diagnostics
7.2.1 Advanced Cell Diagnostics Profile
7.2.2 Advanced Cell Diagnostics Main Business
7.2.3 Advanced Cell Diagnostics Circulating Tumor Cell Diagnostics Products, Services and Solutions
7.2.4 Advanced Cell Diagnostics Circulating Tumor Cell Diagnostics Revenue (US$ Million) & (2019-2024)
7.2.5 Advanced Cell Diagnostics Recent Developments
7.3 Aviva Biosciences
7.3.1 Aviva Biosciences Profile
7.3.2 Aviva Biosciences Main Business
7.3.3 Aviva Biosciences Circulating Tumor Cell Diagnostics Products, Services and Solutions
7.3.4 Aviva Biosciences Circulating Tumor Cell Diagnostics Revenue (US$ Million) & (2019-2024)
7.3.5 Biocept Inc Recent Developments
7.4 Biocept Inc
7.4.1 Biocept Inc Profile
7.4.2 Biocept Inc Main Business
7.4.3 Biocept Inc Circulating Tumor Cell Diagnostics Products, Services and Solutions
7.4.4 Biocept Inc Circulating Tumor Cell Diagnostics Revenue (US$ Million) & (2019-2024)
7.4.5 Biocept Inc Recent Developments
7.5 Biofluidica Inc.
7.5.1 Biofluidica Inc. Profile
7.5.2 Biofluidica Inc. Main Business
7.5.3 Biofluidica Inc. Circulating Tumor Cell Diagnostics Products, Services and Solutions
7.5.4 Biofluidica Inc. Circulating Tumor Cell Diagnostics Revenue (US$ Million) & (2019-2024)
7.5.5 Biofluidica Inc. Recent Developments
7.6 CellTraffix Inc.
7.6.1 CellTraffix Inc. Profile
7.6.2 CellTraffix Inc. Main Business
7.6.3 CellTraffix Inc. Circulating Tumor Cell Diagnostics Products, Services and Solutions
7.6.4 CellTraffix Inc. Circulating Tumor Cell Diagnostics Revenue (US$ Million) & (2019-2024)
7.6.5 CellTraffix Inc. Recent Developments
7.7 Clearbridge BioMedics Pte Ltd
7.7.1 Clearbridge BioMedics Pte Ltd Profile
7.7.2 Clearbridge BioMedics Pte Ltd Main Business
7.7.3 Clearbridge BioMedics Pte Ltd Circulating Tumor Cell Diagnostics Products, Services and Solutions
7.7.4 Clearbridge BioMedics Pte Ltd Circulating Tumor Cell Diagnostics Revenue (US$ Million) & (2019-2024)
7.7.5 Clearbridge BioMedics Pte Ltd Recent Developments
7.8 Epic Sciences Inc.
7.8.1 Epic Sciences Inc. Profile
7.8.2 Epic Sciences Inc. Main Business
7.8.3 Epic Sciences Inc. Circulating Tumor Cell Diagnostics Products, Services and Solutions
7.8.4 Epic Sciences Inc. Circulating Tumor Cell Diagnostics Revenue (US$ Million) & (2019-2024)
7.8.5 Epic Sciences Inc. Recent Developments
7.9 Fluxion Biosciences Inc.
7.9.1 Fluxion Biosciences Inc. Profile
7.9.2 Fluxion Biosciences Inc. Main Business
7.9.3 Fluxion Biosciences Inc. Circulating Tumor Cell Diagnostics Products, Services and Solutions
7.9.4 Fluxion Biosciences Inc. Circulating Tumor Cell Diagnostics Revenue (US$ Million) & (2019-2024)
7.9.5 Fluxion Biosciences Inc. Recent Developments
7.10 ScreenCell
7.10.1 ScreenCell Profile
7.10.2 ScreenCell Main Business
7.10.3 ScreenCell Circulating Tumor Cell Diagnostics Products, Services and Solutions
7.10.4 ScreenCell Circulating Tumor Cell Diagnostics Revenue (US$ Million) & (2019-2024)
7.10.5 ScreenCell Recent Developments
7.11 Silicon Biosystems
7.11.1 Silicon Biosystems Profile
7.11.2 Silicon Biosystems Main Business
7.11.3 Silicon Biosystems Circulating Tumor Cell Diagnostics Products, Services and Solutions
7.11.4 Silicon Biosystems Circulating Tumor Cell Diagnostics Revenue (US$ Million) & (2019-2024)
7.11.5 Silicon Biosystems Recent Developments
7.12 Sysmex Corporation
7.12.1 Sysmex Corporation Profile
7.12.2 Sysmex Corporation Main Business
7.12.3 Sysmex Corporation Circulating Tumor Cell Diagnostics Products, Services and Solutions
7.12.4 Sysmex Corporation Circulating Tumor Cell Diagnostics Revenue (US$ Million) & (2019-2024)
7.12.5 Sysmex Corporation Recent Developments
7.13 Greiner Bio-One GmbH
7.13.1 Greiner Bio-One GmbH Profile
7.13.2 Greiner Bio-One GmbH Main Business
7.13.3 Greiner Bio-One GmbH Circulating Tumor Cell Diagnostics Products, Services and Solutions
7.13.4 Greiner Bio-One GmbH Circulating Tumor Cell Diagnostics Revenue (US$ Million) & (2019-2024)
7.13.5 Greiner Bio-One GmbH Recent Developments
7.14 AdnaGen AG
7.14.1 AdnaGen AG Profile
7.14.2 AdnaGen AG Main Business
7.14.3 AdnaGen AG Circulating Tumor Cell Diagnostics Products, Services and Solutions
7.14.4 AdnaGen AG Circulating Tumor Cell Diagnostics Revenue (US$ Million) & (2019-2024)
7.14.5 AdnaGen AG Recent Developments
7.15 Apocell Inc
7.15.1 Apocell Inc Profile
7.15.2 Apocell Inc Main Business
7.15.3 Apocell Inc Circulating Tumor Cell Diagnostics Products, Services and Solutions
7.15.4 Apocell Inc Circulating Tumor Cell Diagnostics Revenue (US$ Million) & (2019-2024)
7.15.5 Apocell Inc Recent Developments
7.16 Biocep Ltd
7.16.1 Biocep Ltd Profile
7.16.2 Biocep Ltd Main Business
7.16.3 Biocep Ltd Circulating Tumor Cell Diagnostics Products, Services and Solutions
7.16.4 Biocep Ltd Circulating Tumor Cell Diagnostics Revenue (US$ Million) & (2019-2024)
7.16.5 Biocep Ltd Recent Developments
7.17 Canopus Bioscience Ltd
7.17.1 Canopus Bioscience Ltd Profile
7.17.2 Canopus Bioscience Ltd Main Business
7.17.3 Canopus Bioscience Ltd Circulating Tumor Cell Diagnostics Products, Services and Solutions
7.17.4 Canopus Bioscience Ltd Circulating Tumor Cell Diagnostics Revenue (US$ Million) & (2019-2024)
7.17.5 Canopus Bioscience Ltd Recent Developments
7.18 Creatv Microtech Inc
7.18.1 Creatv Microtech Inc Profile
7.18.2 Creatv Microtech Inc Main Business
7.18.3 Creatv Microtech Inc Circulating Tumor Cell Diagnostics Products, Services and Solutions
7.18.4 Creatv Microtech Inc Circulating Tumor Cell Diagnostics Revenue (US$ Million) & (2019-2024)
7.18.5 Creatv Microtech Inc Recent Developments
7.19 Ikonisys Inc
7.19.1 Ikonisys Inc Profile
7.19.2 Ikonisys Inc Main Business
7.19.3 Ikonisys Inc Circulating Tumor Cell Diagnostics Products, Services and Solutions
7.19.4 Ikonisys Inc Circulating Tumor Cell Diagnostics Revenue (US$ Million) & (2019-2024)
7.19.5 Ikonisys Inc Recent Developments
7.20 IV Diagnostics Inc
7.20.1 IV Diagnostics Inc Profile
7.20.2 IV Diagnostics Inc Main Business
7.20.3 IV Diagnostics Inc Circulating Tumor Cell Diagnostics Products, Services and Solutions
7.20.4 IV Diagnostics Inc Circulating Tumor Cell Diagnostics Revenue (US$ Million) & (2019-2024)
7.20.5 IV Diagnostics Inc Recent Developments
7.21 Miltenyi Biotech GmbH
7.21.1 Miltenyi Biotech GmbH Profile
7.21.2 Miltenyi Biotech GmbH Main Business
7.21.3 Miltenyi Biotech GmbH Circulating Tumor Cell Diagnostics Products, Services and Solutions
7.21.4 Miltenyi Biotech GmbH Circulating Tumor Cell Diagnostics Revenue (US$ Million) & (2019-2024)
7.21.5 Miltenyi Biotech GmbH Recent Developments
7.22 Nanostring Technologies Inc
7.22.1 Nanostring Technologies Inc Profile
7.22.2 Nanostring Technologies Inc Main Business
7.22.3 Nanostring Technologies Inc Circulating Tumor Cell Diagnostics Products, Services and Solutions
7.22.4 Nanostring Technologies Inc Circulating Tumor Cell Diagnostics Revenue (US$ Million) & (2019-2024)
7.22.5 Nanostring Technologies Inc Recent Developments
7.23 Rarecells Diagnostics.
7.23.1 Rarecells Diagnostics. Profile
7.23.2 Rarecells Diagnostics. Main Business
7.23.3 Rarecells Diagnostics. Circulating Tumor Cell Diagnostics Products, Services and Solutions
7.23.4 Rarecells Diagnostics. Circulating Tumor Cell Diagnostics Revenue (US$ Million) & (2019-2024)
7.23.5 Rarecells Diagnostics. Recent Developments
7.24 Vitatex Inc
7.24.1 Vitatex Inc Profile
7.24.2 Vitatex Inc Main Business
7.24.3 Vitatex Inc Circulating Tumor Cell Diagnostics Products, Services and Solutions
7.24.4 Vitatex Inc Circulating Tumor Cell Diagnostics Revenue (US$ Million) & (2019-2024)
7.24.5 Vitatex Inc Recent Developments
8 Industry Chain Analysis
8.1 Circulating Tumor Cell Diagnostics Industrial Chain
8.2 Circulating Tumor Cell Diagnostics Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Circulating Tumor Cell Diagnostics Sales Model
8.5.2 Sales Channel
8.5.3 Circulating Tumor Cell Diagnostics Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
Janssen Diagnostics
Advanced Cell Diagnostics
Aviva Biosciences
Biocept Inc
Biofluidica Inc.
CellTraffix Inc.
Clearbridge BioMedics Pte Ltd
Epic Sciences Inc.
Fluxion Biosciences Inc.
ScreenCell
Silicon Biosystems
Sysmex Corporation
Greiner Bio-One GmbH
AdnaGen AG
Apocell Inc
Biocep Ltd
Canopus Bioscience Ltd
Creatv Microtech Inc
Ikonisys Inc
IV Diagnostics Inc
Miltenyi Biotech GmbH
Nanostring Technologies Inc
Rarecells Diagnostics.
Vitatex Inc
听
听
*If Applicable.
